索拉非尼——一种前景广阔的小分子药物？ - Suppr

Sorafenib - a small molecule with big promise?

作者信息

Tadmor Tamar, Tallman Martin S, Polliack Aaron

机构信息

Hematology-Oncology Unit, Bnai-Zion Medical Center, Haifa, Israel.

出版信息

Leuk Lymphoma. 2010 Feb;51(2):181-2. doi: 10.3109/10428190903470893.

DOI:10.3109/10428190903470893

PMID:20001865

Abstract

摘要

相似文献

Sorafenib - a small molecule with big promise?

Leuk Lymphoma. 2010 Feb;51(2):181-2. doi: 10.3109/10428190903470893.

A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.

Leuk Lymphoma. 2010 Feb;51(2):252-60. doi: 10.3109/10428190903585286.

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.

Cancer Sci. 2008 Jul;99(7):1492-8. doi: 10.1111/j.1349-7006.2008.00837.x. Epub 2008 May 12.

Sorafenib (BAY 43-9006): review of clinical development.

Curr Clin Pharmacol. 2006 Sep;1(3):223-8. doi: 10.2174/157488406778249325.

Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis.

Int J Clin Pharmacol Ther. 2009 Jan;47(1):61-4. doi: 10.5414/cpp47061.

Sorafenib in advanced hepatocellular carcinoma.

N Engl J Med. 2008 Dec 4;359(23):2497-8; author reply 2498-9. doi: 10.1056/NEJMc081780.

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.

Leukemia. 2010 Aug;24(8):1437-44. doi: 10.1038/leu.2010.132. Epub 2010 Jun 10.

Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome.

Leuk Lymphoma. 2015 Feb;56(2):395-400. doi: 10.3109/10428194.2014.918970.

Target therapy for hepatocellular carcinoma: is sorafenib for everybody?

J Clin Gastroenterol. 2009 May-Jun;43(5):389-90. doi: 10.1097/MCG.0b013e31819eb9a6.

Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.

Am J Health Syst Pharm. 2008 Jan 15;65(2):123-31. doi: 10.2146/ajhp060661.

引用本文的文献

Elucidation of the Molecular Mechanisms Underlying Sorafenib-Induced Hepatotoxicity.

Oxid Med Cell Longev. 2020 May 14;2020:7453406. doi: 10.1155/2020/7453406. eCollection 2020.

The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow.

PLoS One. 2018 Jan 5;13(1):e0190525. doi: 10.1371/journal.pone.0190525. eCollection 2018.

Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.

Leuk Lymphoma. 2015;56(9):2690-8. doi: 10.3109/10428194.2014.1003055. Epub 2015 Mar 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Sorafenib - a small molecule with big promise?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Sorafenib - a small molecule with big promise?

作者信息

机构信息

出版信息

相似文献

引用本文的文献